Skip to main content
. Author manuscript; available in PMC: 2022 Jan 27.
Published in final edited form as: Clin Cancer Res. 2020 Jun 29;26(15):3928–3935. doi: 10.1158/1078-0432.CCR-20-0953

Figure 4.

Figure 4.

Addition of trastuzumab improves overall survival in advanced uterine serous carcinoma (USC). Left: Among all patients, OS was 24.4 (CP) versus 29.6 (CP+T) months (HR 0.581, 90% CI 0.339–0.994, p=0.0462). Right-top: Benefit was greatest in those undergoing primary therapy with advanced disease (OS 25.4 months versus not reached, HR 0.492, 90% CI 0.249 – 0.974, p=0.0406). Right-bottom: Benefit was not apparent in the recurrent setting (22.5 versus 25.0 months, HR 0.864, 90% CI 0.355–2.100, p=0.3929).